NCT03473275 (BRAIrdN) is a clinical trial of Cold Pressor test in Hypertension,Essential, sponsored by Centre Hospitalier Universitaire Vaudois.

Who is sponsoring NCT03473275?

NCT03473275 is sponsored by Centre Hospitalier Universitaire Vaudois.

What drugs are being tested in NCT03473275?

Interventions in NCT03473275: Cold Pressor test, PinPrick test.

What condition does NCT03473275 study?

NCT03473275 studies Hypertension,Essential.

Is NCT03473275 still recruiting?

NCT03473275 is currently completed. Last updated 21 February 2023.

Last reviewed 2023-02-21 · How we verify

NCT03473275: BRAIrdN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brain BOLD fMRI in Hypertensive and Normotensive Participants

Completed Last updated 21 February 2023

What this trial tests

trial testing Cold Pressor test in Hypertension,Essential in 84 participants. Completed in 12 August 2022.

Timeline

16 August 2018

Primary endpoint
12 August 2022

12 August 2022

Quick facts

Lead sponsor	Centre Hospitalier Universitaire Vaudois
Status	Completed
Study type	OBSERVATIONAL
Enrollment	84
Start date	16 August 2018
Primary completion	12 August 2022
Estimated completion	12 August 2022
Sites	1 location across Switzerland

Drugs / interventions tested

Cold Pressor test
PinPrick test

Conditions studied

Hypertension,Essential — all drugs for Hypertension,Essential →

Sponsor

Centre Hospitalier Universitaire Vaudois

Who can join

18 and older, any sex, with Hypertension,Essential. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will explore the brainstem activity in response to stress in hypertensive patients and normotensive subjects. In addition, it will evaluate if the response in hypertensive patients can be modulated by blocking the afferent signalling of sympathetic nervous system from the kidney to the brain achieved by renal denervation. The investigators hypothesize that the change in BOLD signal intensity in response to stress is higher in hypertensive patients than in normotensive subjects and that in patients responsive to renal denervation the change in BOLD signal intensity in response to stress is decreased compared to non-responders or to non-denervated resistant hypertensive patients.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Contrast-enhanced ultrasonography reveals a lower cortical perfusion and a decreased renal flow reserve in hypertensive patients.
Damianaki A, Hendriks-Balk M, Brito W, Polychronopoulou E, et al · · 2024 · cited 6× · PMID 37553142 · DOI 10.1093/ndt/gfad158
Contrast-Enhanced Ultrasonography Enables the Detection of a Cold Pressor Test-Induced Increase in Renal Microcirculation in Healthy Participants.
Hendriks-Balk MC, Damianaki A, Polychronopoulou E, Brito W, et al · · 2022 · cited 6× · PMID 35669471 · DOI 10.3389/fcvm.2022.899327
Determinants of Renal Micro-Perfusion as Assessed with Contrast-Enhanced Ultrasound in Healthy Males and Females.
Ulpiano Trillig A, Damianaki A, Hendriks-Balk M, Brito W, et al · · 2023 · cited 2× · PMID 37373834 · DOI 10.3390/jcm12124141
In Patients With Hypertension, the Cortical Perfusion Index Measured by Contrast Enhanced Ultrasound Reveals a Sexual Dimorphism.
Damianaki A, Hendriks-Balk M, Brito W, Polychronopoulou E, et al · · 2025 · PMID 39895553 · DOI 10.1161/jaha.124.039306

Verify or expand the search:

Other trials of Cold Pressor test

Trials testing the same drug.

NCT05345548 — Sensitivity, Threshold, Tolerance and Pain Recognition in Schizophrenia Patients and Their Relatives. · NA · unknown

Other recruiting trials for Hypertension,Essential

Currently open trials in the same condition.

NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature · recruiting
NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
NCT06205628 — Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension · Phase 1 · active not recruiting
NCT04505618 — Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease · NA · recruiting
NCT04625569 — Genetic of Response to Acute Saline Load Test in Hypertension (Naload) · recruiting

Other Centre Hospitalier Universitaire Vaudois trials

Trials by the same sponsor.

NCT07427511 — SwissNeuroRehab - HDHI · NA · recruiting
NCT07263438 — Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a · Phase 2 · recruiting
NCT07139756 — Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension · not yet recruiting
NCT07109388 — Comparison of Pericapsular Nerve Group (PENG) Block With a Combined Femoral, Sciatic, Lateral Femoral Cutaneous Nerve Bl · NA · not yet recruiting
NCT07268378 — Supervision of Clinicians in Oncology by Psycho-oncologists : Evaluation · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03473275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Vaudois
Last refreshed: 21 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03473275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing